The impact of temporal variability of biochemical markers PAPP-A and free β-hCG on the specificity of the first-trimester down syndrome screening: A Croatian retrospective study

BMC Research Notes

Volumn 3, Issue , 2010, Pages

  Tišlarić Medenjak, Dubravka ^a   Zec, Ivana ^a   Šimundić, Ana Maria ^a   Sabolovi Rudman, Senka ^a   Kos, Milan ^b   Megla, Željka Bukovec ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b Out patient Clinics of Gynecology VILI   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955570667     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-3-194     Document Type: Article

References (27)

1. One stop clinic for assessment of fetal risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. K Spencer CE Spencer M Power A Moakes KH Nicolaides, Br J Obstet Gynaecol 1999 107 1271 1275
2. Combined ultrasound and biochemical screening for Down syndrome: a Scotish multicentre stydy. JA Crossley DA Aitken AD Cameron E McBride JM Connor, Br J Obstet Gynaecol 2002 109 667 676
3. The first-trimester 'combined-test' for the detection of Down syndrome pregnancies in 4939 uselected pregnancies. K Schuchter E Hafner G Stangl M Metzenbauer D Hofinger K Philipp, Prenat Diagn 2002 22 211 215 10.1002/pd.288 11920896
4. First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. F Muller C Benatar F Audibert N Roussel S Dreux H Cuckle, Prenat Diagn 2003 23 833 836 10.1002/pd.700 14558029
5. First trimester Down syndrome screening: Distribution of markers and comparison of assays for quantification of pregnancy-associated plasma protein-A. KR Wøjdemann SO Larsen L Rode A Shalmi K Sunberg M Christiansen A Tabor, Scand J Clin Lab Invest 2006 66 101 112 10.1080/00365510500406902 16537243
6. Covariables in first trimester serum screening. IM De Graaf SH Cuckle E Pajkrt NJ Leschot OP Bleker JMM van Lith, Prenat Diagn 2000 20 186 189 10.1002/(SICI)1097-0223(200003)20:3<186::AID-PD776>3.0.CO;2-A 10719318
7. Maternal weight correction of maternal serum PAPP-A and free β-hCG when screening for trisomy 21 in the first trimester of pregnancy. K Spencer R Bindra KH Nicolaides, Prenat Diagn 2003 23 851 855 10.1002/pd.708 14558032
8. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. K Spencer R Bindra AM Cacho KH Nicolaides, Prenat Diagn 2004 24 169 173 10.1002/pd.819 15057947
9. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: A study on Oriental, Asian and Afro-Caribbean populations. K Spencer V Heath A El-Sheikhah CYT Ong KH Nicolaides, Prenat Diagn 2005 25 365 369 10.1002/pd.1153 15906426
10. Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. NJ Wald S Rish AK Hackshaw, Prenat Diagn 2003 23 588 592 10.1002/pd.627 12868090
11. The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. K Spencer CYT Ong AWJ Liao D Papademetriou KH Nicolaides, Prenat Diagn 2000 20 673 675 10.1002/1097-0223(200008)20:8<673::AID-PD880>3.0. CO;2-5 10951481 (Pubitemid 30598916)
12. The influence of maternal insulin-dependent diabetes mellitus on fetal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. K Spencer S Cicero A Atzei C Otigbah KH Nicolaides, Prenat Diagn 2005 25 927 929 10.1002/pd.1229 16088864
13. The influence of parity and gravidity on first trimester markers of chromosomal abnormality. K Spencer CYT Ong AWJ Liao KH Nicolaides, Prenat Diagn 2000 20 792 794 10.1002/1097-0223(200010)20:10<792::AID-PD914>3.0.CO;2-5 11038455
14. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. AW Liao W Heath N Kametas K Spencer KH Nicolaides, Hum Reprod 2001 16 7 1501 1504 10.1093/humrep/16.7.1501 11425838
15. Serum PAPP-A levels at 10-14 weeks of gestation are altered in women after assisted conception. N Tul Novak-Antoli Prenat Diagn 2006 26 1206 1211 10.1002/pd.1589 17075793
16. Screening for Down syndrome:changes in marker levels and detection rates between first and second trimesters. E Berry DA Aitken YA Crossley JN Macri JM Connor, Br J Obstet Gynaecol 1997 104 811 817 9236646
17. First trimester Down syndrome screening: Component analytes and timing for optimal performance. KD Wenstrom, Semin Perinatol 2005 29 195 202 10.1053/j.semperi.2005.06.002 16104668
18. Appropriate biochemical parameters in first-trimester screening for Down syndrome. HS Cuckle JMM van Lith, Prenat Diagn 1999 19 505 512 10.1002/(SICI)1097-0223(199906)19:6<505::AID-PD572>3.0.CO;2-6 10416963
19. Meta-analysis of first trimester Down syndrome screening studies: free -human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol. MI Evans DA Krantz TW Hallahan RS Galen, Am J Obstet Gynecol 2007 196 198 205 10.1016/j.ajog.2006.08.001 17346522
20. Combined ultrasound and biochemical screening for fetal aneuploidy at 10-14 weeks of pregnancy: first results of test performance in Croatia. D Tilari-Medenjak V Koec M Kos V Latin V Harni B Lovri, et al. Gynaecol Perinatol 2008 17 195 200
21. Combined ultrasound-biochemical screening of fetal trisomies in the first trimester and double biochemical screening in the second trimester in unaffected pregnancies. D Tilari-Medenjak I Zec V Koec T Ivievi-Bakuli K Kuna R Herman,, et al. Gynaecol Perinatol 2009 18 123 131
22. UK NEQAS for peptide and related substances. J Seth CM Sturgeon AR Aellis R Al-Sadie M Logan, Annual Report 2000 Sheffield: UK NEQAS
23. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free β-hCG and PAPP-A assays. K Spencer, Ann Clin Biochem 2005 42 30 40 10.1258/0004563053026880 15802030
24. ACMG Technical standards and guidelines: Prenatal screening for Down syndrome. GE Palomaki LA Bradley GA McDowell, Genet Med 2005 7 344 354 10.1097/01.GIM.0000167808.96439.F3 15915087
25. Risk, a QC parameter. K Spencer, DS News 2003 10 30 31
26. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient specific risks and detection rates for Down's syndrome. K Spencer JA Crossley DA Aitken ABJ Nix FDJ Dunstan K Williams, Ann Clin Biochem 2003 40 219 231 10.1258/000456303321610501 12803832
27. Screening for chromosomal anomalies in the first trimester: does repeat maternal screening improve detection rates? K Spencer HS Cuckle, Prenat Diagn 2002 22 903 906 10.1002/pd.441 12378574